Randomized phase II study of docetaxel + bevacizumab or pemetrexed + bevacizumab for elderly non-squamous non-small-cell lung cancer. (TORG1323)

Trial Profile

Randomized phase II study of docetaxel + bevacizumab or pemetrexed + bevacizumab for elderly non-squamous non-small-cell lung cancer. (TORG1323)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 16 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top